AU2006254333B2 - Anti-IL2 antibodies - Google Patents

Anti-IL2 antibodies Download PDF

Info

Publication number
AU2006254333B2
AU2006254333B2 AU2006254333A AU2006254333A AU2006254333B2 AU 2006254333 B2 AU2006254333 B2 AU 2006254333B2 AU 2006254333 A AU2006254333 A AU 2006254333A AU 2006254333 A AU2006254333 A AU 2006254333A AU 2006254333 B2 AU2006254333 B2 AU 2006254333B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
monoclonal antibody
humanized monoclonal
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006254333A
Other languages
English (en)
Other versions
AU2006254333A1 (en
Inventor
Patrick Bauerle
John Lumsden
Stefan Pflanz
Tobias Raum
Jorg Volkland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of AU2006254333A1 publication Critical patent/AU2006254333A1/en
Application granted granted Critical
Publication of AU2006254333B2 publication Critical patent/AU2006254333B2/en
Assigned to AMGEN RESEARCH (MUNICH) GMBH reassignment AMGEN RESEARCH (MUNICH) GMBH Request to Amend Deed and Register Assignors: MICROMET AG
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
AU2006254333A 2005-06-01 2006-05-31 Anti-IL2 antibodies Ceased AU2006254333B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011845 2005-06-01
EP05011845.4 2005-06-01
PCT/EP2006/005194 WO2006128690A1 (en) 2005-06-01 2006-05-31 Anti-il2 antibodies

Publications (2)

Publication Number Publication Date
AU2006254333A1 AU2006254333A1 (en) 2006-12-07
AU2006254333B2 true AU2006254333B2 (en) 2011-02-17

Family

ID=37025008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006254333A Ceased AU2006254333B2 (en) 2005-06-01 2006-05-31 Anti-IL2 antibodies

Country Status (15)

Country Link
US (1) US7964707B2 (https=)
EP (1) EP1888644A1 (https=)
JP (1) JP5414271B2 (https=)
KR (1) KR101340559B1 (https=)
CN (1) CN101189265B (https=)
AU (1) AU2006254333B2 (https=)
BR (1) BRPI0610912A2 (https=)
CA (1) CA2609234C (https=)
IL (1) IL187316A0 (https=)
MX (1) MX2007014565A (https=)
NO (1) NO20076568L (https=)
NZ (1) NZ563213A (https=)
RU (1) RU2425054C2 (https=)
WO (1) WO2006128690A1 (https=)
ZA (1) ZA200709456B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433967A3 (en) * 2009-03-16 2013-05-01 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
CA2778552A1 (en) * 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
CA2869477C (en) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
CN106170496B (zh) 2013-12-12 2019-10-08 Umc乌得勒支控股有限公司 针对纤连蛋白-eda的免疫球蛋白样分子
EP3088517B1 (en) * 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
DK3166973T3 (da) 2014-07-10 2020-04-06 Univ Zuerich Immunstimulerende monoklonale antistoffer mod human interleukin-2
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
WO2017122130A1 (en) 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
CN109689684B (zh) * 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
AU2017335771A1 (en) * 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
KR102099593B1 (ko) * 2017-05-25 2020-04-13 기초과학연구원 항-인간 인터루킨-2 항체 및 이의 용도
IL272864B2 (en) 2017-08-31 2024-03-01 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis
WO2020187848A1 (en) 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
JP7245358B2 (ja) 2019-06-10 2023-03-23 山東博安生物技術股▲ふん▼有限公司 抗ｃｄ２５抗体及びその適用
EP4314032A1 (en) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides
CN113248610B (zh) * 2021-05-14 2022-08-16 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
JP2025534285A (ja) 2022-09-29 2025-10-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
CN115850471B (zh) * 2022-10-13 2026-04-07 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用
CN119661706B (zh) * 2024-01-31 2025-11-28 康立泰生物医药(青岛)有限公司 一种抗人白介素2抗体及其应用
CN118515762B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 特异性结合il-2的抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
EP1290031A4 (en) * 2000-05-24 2004-09-22 Smithkline Beecham Corp SIALOADHESIN FACTOR ANTIBODIES
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
NZ580256A (en) * 2003-08-13 2011-07-29 Novartis Vaccines & Diagnostic Prion-specific peptide reagents comprising the sequence KKRPKPGG

Also Published As

Publication number Publication date
BRPI0610912A2 (pt) 2008-12-02
NO20076568L (no) 2008-02-19
ZA200709456B (en) 2008-08-27
WO2006128690A1 (en) 2006-12-07
MX2007014565A (es) 2008-02-11
KR101340559B1 (ko) 2013-12-11
AU2006254333A1 (en) 2006-12-07
US20080317746A1 (en) 2008-12-25
JP2008542321A (ja) 2008-11-27
CA2609234C (en) 2014-04-22
KR20080032046A (ko) 2008-04-14
CA2609234A1 (en) 2006-12-07
NZ563213A (en) 2009-07-31
EP1888644A1 (en) 2008-02-20
RU2007143996A (ru) 2009-07-20
CN101189265A (zh) 2008-05-28
RU2425054C2 (ru) 2011-07-27
JP5414271B2 (ja) 2014-02-12
CN101189265B (zh) 2012-07-04
IL187316A0 (en) 2008-04-13
US7964707B2 (en) 2011-06-21

Similar Documents

Publication Publication Date Title
JP7057843B2 (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
AU2006254333B2 (en) Anti-IL2 antibodies
CN109715667B (zh) 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
US9447182B2 (en) Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates
US20160194402A1 (en) Cd70-binding peptides and method, process and use relating thereto
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
US20250051473A1 (en) Anti-cd38 binding molecules and uses thereof
EP3112462B1 (en) Novel bispecific antibody binding to human tlr2 and human tlr4
CN118459587A (zh) 抗cd47抗体及其应用
KR20230117178A (ko) T 세포 인게이저 치료제의 개발 및 적용
US20240269276A1 (en) Specific binding protein targeting pd-l1 and cd73
CN120554509A (zh) 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
CN122003439A (zh) 抗IL-4Rα抗体及其用途
CN122003442A (zh) 抗IL-4Rα/TSLP抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ AMGEN RESEARCH (MUNICH) GMBH .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired